Approximately 60% of pediatric patients with secondary CML-BP showed mutations in the tyrosine kinase domain of the BCR::ABL1 gene [6]; the TKI must therefore be selected according to the tyrosine kinase domain mutation profile. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.